Vogenx (VOGX) prices IPO at $13, raising $81.25 million on Nasdaq
As seen on the 24/7 Wall St. homepage on August 12, 2026.
Vogenx prices IPO at $13, raising $81.25 million
Vogenx's IPO pulled in $81.25 million, giving investors a fresh public pure-play on metabolic disease at a moment when biotech listings are scarce. Shares start trading now, with JonesTrading running the book.
Continue ReadingShow less
Vogenx, Inc. raised $81.25 million in its Nasdaq debut, with JonesTrading running the book on the deal.
The offering positions Vogenx as a rare pure-play on metabolic disease to reach public markets, arriving at a moment when biotech listings have been scarce. For investors looking for dedicated exposure to that therapeutic area, the IPO opens a window that has been largely closed.
Sponsored
_________________________________
What's Your Number...?
Here's a question most people 5y from retirement can't answer: at your current savings rate, how much do you need, and how long will it actually last? A good advisor can put a date on that in a single meeting. SmartAsset's free quiz matches you with up to three fiduciary advisors serving your area, so you can get YOUR retirement number now (sponsor)
__________________________________________
With the shares now live, the immediate question is how the stock holds up relative to its $13 offering price in early trading. A clean hold or move above that level signals strong aftermarket demand and sets the tone for other biotech candidates.
The deal terms are drawn from an SEC filing dated August 12, 2026, which serves as the authoritative record of pricing, share count, and proceeds.
Mentioned: VOGX